Orofacial clefting (OFC) is a common craniofacial birth defect that has a prevalence of
Orofacial clefting (OFC) is a common congenital abnormality which has a prevalence of evaluated the utility of gene-panel sequencing for resolving molecular diagnoses in 48 general and consider patterns of sequence coverage across the FGD1 gene in particular 49 as an illustrative example. 50 Materials and methods 51 0.1 Patients phenotype 52 DNA samples from 14 unrelated male patients each with a tentative clinical diagnosis of 53 AAS were obtained through the Operation Smile clinic in Bogota, Colombia (Table 1) . 54 All patients presented with either unilateral or bilateral cleft lip (CL) and nine patients 55 also presented with complete cleft palate (CP) and one with incomplete CP. Shawl scrotum and cryptorchidism phenotypes. We considered variants in a comprehensive set 141 of 918 genes combined from three searches as follows: (1) A list of 112 candidate genes 142 prepared by literature search, nucleating from HGMD v.2016.2 [12] , using the following 143 keywords (and Human Phenotype Ontology, HPO terms): Cleft, Shawl Scrotum Variant annotation revealed that no variants with known clinical effects related to 155 any of the phenotypes were present in the sample. With the expectation that the 156 variants associated with these syndromic phenotypes are likely to be rare and highly 157 penetrant, we further considered only novel variants. Additional variants were excluded 158 using the following criteria: (1) All synonymous variants located outside of the 159 exon-intron boundaries were excluded. Synonymous variants within 10bp of either 160 4/36 donor-splice site or acceptor-splice were retained and analyzed as potential splicing 161 variants; (2) Variants located beyond 10 base pairs 5 or 3 of exons were dealt with as 162 noncoding variants and excluded; (3) Non-frameshift deletion/insertion variants were 163 excluded as they were unlikely to be causal in these cases; (4) Variants with read depth 164 of coverage of less than 10 were excluded from further consideration as potential false 165 positive; (5) All novel variants were examined visually in IGV and any which suggested 166 low-quality genotype calls and/or errors in alignment due to, for example, extensive 167 homopolymer sequences in the region, were excluded from further consideration. We 168 considered evidence of pathogenicity using four functional prediction models (SIFT, 169 PP-2, LRT and FATHMM), two conservation models (GERP ++ and Phylop) and three 170 combined scores (M-CAP, CADD and RadialSVM). 171 To priorities candidate causal variants for each individual a score which combines 172 evidence across the main predictive models was used to generate a ranked order (Table 173 3). For each variant the predictive scores from the selected models were transformed to 174 the single combined score Ψ i according to the formula:
where S i is the score function defined as: 176 (2)
The θ(x i ) is the pathogenicity or conservation score for variant x for the i th Results 184 0.6 FGD1 gene coverage 185 Figure 1 presents the heatmap of normalised read-depth coverage across all 18 exons of 186 the FGD1 gene for the samples. Also shown here is the corresponding data from whole 187 exome sequences in six independent samples. These data suggest that the TruSight One 188 capture kit does not provide a uniform capture across all 18 exons of this gene.
189
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227
The ranking strategy applied to prioritise putatively causal variants revealed the Floating-Harbor syndrome (FLHS, #136140) [31] . Patients with SRCAP mutation 232 present with delayed bone age and speech development, short stature, triangular faces 233 and deep-set eyes with long eyelashes. The ears in FLHS patients are posteriorly 234 rotated, however the facial characteristics of the patients are age-related and change over 235 the time. Unilateral cleft and cryptorchidism have also been reported in the context of 236 the disease [31] . The majority of nonsense and frameshift SRCAP mutations that have 237 been identified in FLHS patients map to the exon 34 of the gene [32] . As exon 34 is the 238 last exon of the SRCAP gene, these mutations escape the nonsense-mediated mRNA 239 decay and lead to pathogenicity [33] . Given that identified mutation maps to the exon 240 34 of SRCAP and the extent of phenotypic similarity between the proband's phenotype 241 and FLHS features, the functional impact of the variant merits further investigation. KDM6A mutations underlie 6.2% of KABUK2 incidence. They also suggested that 248 arched eyebrows are less common among KDM6A mutants but short stature and 249 postnatal growth retardation is the consistent feature among all patients with KDM6A 250 mutations. Genitourinary anomalies are common among KABUK2 patients but shawl 251 scrotum has never been reported in the context of the disease. Furthermore, congenital 252 mental retardation in combination with multisystemic anomalies involving heart and (HP:0000028) as described in the Table 1 . Fourteen variants were prioritised through 273 the filtering strategy ( Table 3 ). The visual inspection of reads in IGV to confirm the 274 authenticity of variants revealed the top three candidates as MYO7A:c.2441G>A (rank 275 2), RYR1 :c.2543C>T (rank 6) and PIK3R1 :c.235A>G (rank 12).
276
MYO7A encodes an unconventional myosin with a very short tail that plays an 277 important role in cellular movements [35] . Heterozygous mutations of MYO7A are 278 identified to underlie nonsyndromic progressive hearing loss known as autosomal 279 dominant deafness-11 (DFNA11, OMIM # 601317) [36] . Considering the lack of 280 phenotypic similarity between the DFNA11 and the patient's main features and also 281 absence of vestibular symptoms in the proband CL022, it is highly unlikely that 282 7/36
MYO7A:c.2441G>A is causal in the context of the disease. The variant, therefore, was 283 excluded from further follow-up.
284
RYR1 encodes a ryanodine receptor which acts as a calcium release channel in the 285 sarcoplasmic reticulum of skeletal muscles [37] . Heterozygous mutations of RYR1 have 286 been identified to underlie Central core disease (CCD, OMIM # 117000) [38] and a 287 form of malignant hyperthermia known as King-Denborough syndrome (OMIM # 288 145600) [39] . Facial and genitourinary dysmorphisms have never been reported in the 289 context of CCD or King-Denborough syndrome. Furthermore, patients with pathological 290 RYR1 usually present with additional muscle and soft tissue involvement including 291 neonatal hypotonia, muscle atrophy and muscle weakness in CCD or muscle rigidity and 292 rhabdomyolysis in King-Denborough syndrome [40] . These phenotypes are absent in the 293 proband CL022 and therefore, given the inconsistency of symptoms between the 294 patient's main features and the symptoms associated with the RYR1 mutations, it is 295 unlikely that the RYR1 :c.2543C>T is aetiological in the context of the disease.
296
Heterozygous mutations of PIK3R1 are identified to underlie the autosomal 297 dominant SHORT syndrome (OMIM # 269880). PIK3R1 encodes the 298 phosphatidylinositol 3-kinase that plays an important role in growth signalling 299 pathways. This lipid kinase phosphorylates the inositol ring of phosphatidylinositol and 300 thereby triggers the second messenger in the insulin signalling pathway [41] . Patients 301 with the SHORT syndrome are present with short stature, triangular faces, 302 micrognathia, telecanthus and deep-set eyes [42] . Bone maturation and teething are 303 usually delayed among SHORT patients, but patients are intellectually normal [43] .
304
CLP and genitourinary abnormalities including shawl scrotum and cryptorchidism have 305 never been reported in the context of the SHORT syndrome. Despite the presence of 306 telecanthus and short stature in the proband CL022, the phenotypic similarity between 307 the SHORT syndrome and patients main features are negligible and therefore the 308 PIK3R1 :c.235A>G is unlikely to be relevant to the patient's phenotype.
309
In conclusion, neither of patients phenotype was consistent with the syndromes 310 associated to these genes and therefore a molecular diagnosis could not be established in 311 this patient. and cryptorchidism (HP:0000028). The patient is also present with anophthalmia 317 (HP:0000528) and oesophagal atresia (HP:0002032) ( Table 1) . Fifteen novel variants 318 were prioritised through the filtering strategy, of which two variants including 319 CREBBP :c.7037A>C (rank 4) and OFD1 :c.2610G>C (rank 7) were identified as 320 putatively causal with respect to the patient's phenotype (Table 3) .
321
Heterozygous mutations of CREBBP have been identified to underlie autosomal 322 dominant Rubinstein-Taybi syndrome 1 (RSTS1, # 180849). Patients with pathogenic 323 CREBBP mutations present with multiple congenital anomalies including dysmorphic 324 facial features, broad and angulated thumbs, postnatal growth deficiency, shawl scrotum 325 and cryptorchidism [44] . Facial dysmorphisms in RSTS1 patients Occasionally involves 326 cleft lip [45] , but anophthalmia has never been reported in the context of the disease.
327
Given the lack of convincing phenotypic similarity between the patient's main features 328 and RSTS1, it seems unlikely that CREBBP :c.7037A>C underlies the patient's hypertelorism, telecanthus and polycystic kidney disease [46, 47] . Shawl scrotum and 335 cryptorchidism have been rarely documented in the context of the disease as pathogenic 336 OFD1 mutations leads to premature death in hemizygous males [47] . Intriguingly, 337 Tsurusaki et al. [48] reported a lethal case hemizygous male in a family ascertained for 338 OFD1 mutation in a hemizygous male with preterm delivery (33 weeks reported that the patient died 11 hours after birth due to laryngeal anomalies. Genetic 342 analysis of another male patient from the same family with similar phenotype and 343 esophageal abnormalities who were also delivered preterm and died one day after birth 344 revealed a pathogenic splicing mutation at OFD1 :c.2388+1G>C [48] . Given extensive 345 phenotypic similarity between the the patients described by Tsurusaki et al. and the 346 proband CL025 main features it is possible that OFD1 :c.2610G>C (Ψ i =4.5) underlies 347 the patient's condition. One possible explanation for the lack of lethality in the proband 348 CL025 could be the mosaic nature of the mutation in the patient. In fact, the (Table 3) . pathogenic NAGLU mutations present with a range of neurologic conditions including 364 peripheral neuropathy and sensory impairment. The disease has a late age of onset and 365 usually occurs between 18 and 61 years of age [49] . Considering the lack of phenotypic 366 similarity between the patient CL027 main features and CMT2V, it is unlikely that 367 NAGLU :c.311C>A (Ψ i =8) underlies the patient's condition.
368
Heterozygous mutations of TGFB3 have been linked to two autosomal dominant 369 conditions known as Arrhythmogenic right ventricular dysplasia 1 (ARVD1, OMIM # 370 107970) and Loeys-Dietz syndrome 5 (LDS5, # 615582). Clinical presentation in 371 ARVD1 restricts to cardiovascular complications [50] whereas in LDS5 patients present 372 cleft palate in combination with a range of cardiovascular complications including aortic 373 aneurysms [51] . Considering that the proband CL027 does not appear to have 374 cardiovascular complications and given the lack of phenotypic similarity to the 375 syndromes described above, it is highly unlikely that the TGFB3 :c.785G>T (Ψ i =5.5) is 376 causal in the context of the patient's condition. Taken together, we could not 377 conclusively resolve the molecular diagnosis in this patient. (Table 1) . Two variants including the NIPBL:c.7801A>G 383 9/36 (rank 2) and KIRREL3 :c.544A>T (rank 3) revealed to have high quality IGV reads.
384
Heterozygous mutations of NIPBL are identified to underlie autosomal dominant 385 Cornelia de Lange syndrome-1 (CDLS1, OMIM # 122470) [52] . A wide clinical 386 variability for CDLS1 has been described. The CDLS1 patients typically present with 387 multisystem malformations including facial dysmorphisms, upper limb anomalies, 388 developmental delay and mental retardation [53] . Twenty per cent of children with the 389 CDLS1 present with cleft palate [54] and upper limb anomalies and the fifth finger 390 clinodactyly is reported in 74% of cases [55] . Genitourinary anomalies including 391 hypoplastic genitalia and cryptorchidism are fairly common among CDLS1 patients and 392 are reported in 57% and 73% of the male patients respectively [55, 56] . Lalatta et 393 al. [57] reported hypertelorism in a neonatal case of CDLS1 with novel mutation at exon 394 35 of NIPBL. The wide variability in the clinical presentations of the disease renders its 395 diagnosis challenging. Severe forms of CDLS1 are readily diagnosed at an early age 396 (>90% below the age of 2), but diagnosis becomes more challenging as patients grow 397 older [53] . Establishing a diagnosis in the milder form of CDLS1 is even more non-synonymous GRIN2A:c.652C>T mutation is not fully described [59] . Considering 417 incomplete penetrance and variable phenotype reported in the context of GRIN2A 418 mutations [60, 61] , it is possible that identified non-synonymous mutation at GRIN2A: 419 c.136G>A (Ψ i = 4) is causal in the patient. The FESD patients usually present with 420 childhood-onset seizures that may last until adulthood [62] . Considering that 421 phenotyping in the proband CL035 was carried out during infancy further 422 neuropsychological assessment is required in order to establish a diagnosis. (HP:0000506), shawl scrotum (HP:0000049), cryptorchidism (HP:0000028), clinodactyly 427 of the 5th finger (HP:0030084) and heart murmur (HP:0030148) ( Table 1 ). The patient 428 had a low height, and weight percentile for his age and proband's maternal cousin was 429 also present with CLP. Five novel variants were identified as putatively pathogenic 430 ( Table 3 ). Investigation of genotype quality scores in parallel with visual inspection of 431 read alignments for shortlisted variants revealed that SMARCA4 :c.889A>C (rank 4 432 Ψ i = 6, DP = 27, GQ = 31) and ARID1B :c.293A>C (rank 5, Ψ i = 3, DP = 22, GQ = 433 10/36 28 ) are probably spurious calls and therefore they were excluded from further analysis. 434 The genotype quality score for the non-synonymous PTPN11 :c.323C>A (rank 1) 435 variant was also very low (GQ = 28) and considering the low depth of coverage at this 436 site (DP = 11) a reliable basis for a heterozygous call could not be established.
437
Two variants including KMT2D: c.16493C>T (rank 2, Ψ i = 7) and BRCA2 : 438 c.9425A>T (rank 3, Ψ i = 7) were identified to have high read depth and high genotype 439 quality (DP > 80 and GQ = 99) for confident variant analysis.
440
The KMT2D gene encodes a histone methyltransferase that is an important 441 component of ASCOM complex which has been shown to regulate the transcriptional 442 activity of beta-globin and estrogen receptor genes [63, 64] . Heterozygous mutations of 443 KMT2D are identified to underlie autosomal dominant Kabuki syndrome 1 (KABUK1, 444 OMIM # 147920) [65] . Individuals with KABUK1 syndrome present with multiple 445 congenital anomalies and characteristic facial features that typically include highly 446 arched and sparse eyebrows, depressed nasal tip, short columella and large earlobes [66] . 447 Cleft lip and/or cleft palate have been reported in 35% of cases [34] . Genitourinary 448 abnormalities including cryptorchidism and micropenis have been observed in 449 approximately 25% and 10% of male patients, respectively [34, 67] . Clinodactyly of the 450 fifth digit is one of the major skeletal anomalies reported in 50% of patients [67] . (VSD) and Patent ductus arteriosus (PDA)) that result in childhood heart murmur have 459 been identified in 90.6% of Kabuki patients diagnosed prenatally or at an early age [70] . 460 Given the extensive phenotypic similarity between the patient's main features and 461 KABUK1 syndrome and, also high combined rank score for the KMT2D: c.16493C>T 462 mutation (rank 2, Ψ i = 7), it is possible that this variant underlies the patient The BRCA2 gene was primarily included in our tiered gene list since transcriptional 467 dysregulation of BRCA2 are identified to associate with susceptibility to DNA damage 468 and non-syndromic CLP [71] . Given the absence of direct link between BRCA2 469 mutations and the patient's main features, it is possible that the BRCA2 : c.9425A>T 470 is an incidental finding without any implication on the patient's phenotype. Although 471 this variant appears unlikely to have any impact on patient's health, because of the 472 BRCA2 role in familial Breast and ovarian cancer (OMIM #600185), the identified 473 mutation might have a clinical significance for female relatives of the patient. Therefore 474 in compliance with the ACMG guideline for reporting secondary findings [72] , it has 475 been brought to the attention of recruiting clinician as an incidental finding. (Table 1 ). Variant analysis shortlisted 481 six novel mutations in genes including CREBBP, OFD1, TBX4, ATR, ANKRD11 and 482 SALL4 ( Table 3) . Inspection of read alignments in IGV in parallel with the 483 investigation of genotype quality scores revealed that only the ATR:c.3025G>A (rank 4, 484 11/36 Ψ i = 2.5, DP = 56, GQ= 99) appears to be a reliable call. The remaining variants 485 reflect alignment errors and therefore were excluded from further analysis. 486 Heterozygous mutations of the ATR gene have been identified to underlie autosomal 487 dominant cutaneous telangiectasia and cancer syndrome (FCTCS, OMIM # 488 614564) [73] . Patients with pathogenic heterozygous mutations of ATR present with 489 cutaneous telangiectasia and dispersed alopecia during infancy [74] . Given the lack of 490 reported telangiectasies complications in the proband CL039, it is unlikely that 491 heterozygous ATR:c.3025G>A is related to the patient's condition.
492
Homozygous or compound heterozygous mutations of ATR have been reported to 493 cause autosomal recessive Seckel syndrome 1 (SCKL1, OMIM # 210600). Among 494 phenotypic features reported for the proband CL039, cleft lip/cleft palate and 495 hyperactivity have also been documented in SCKL1 patients [75] [76] [77] . Considering that 496 no other non-synonymous mutation was identified in the ATR gene, the patient's 497 condition could not be linked to Seckel syndrome 1. Taken together variant analysis in 498 the patient CL039 failed to identify the causal variant and molecular diagnosis in this 499 patient remained unresolved.
500

Discussion
501
Despite the fact that molecularly confirmed cases of AAS have been entirely attributed 502 to the pathogenic mutations of FGD1, we did not identify any variant with the 503 pathogenic implication in this gene across the samples analysed. Failure to identify 504 FGD1 mutations could be attributed to several factors that are discussed below.
505
Aarskog-Scott syndrome is a rare disorder with extensive phenotypic similarity with 506 other rare phenotypes [8] . Genotype-phenotype correlation of the disease is not fully 507 understood, and molecular diagnosis in only 20% of cases is resolved [8] . Differential 508 diagnosis when molecular aetiology of the disease is inconclusive proved to be 509 challenging. Given the overlapping nature of facial characteristics in rare disorders [78] , 510 the possibility of alternative diagnoses compatible with molecular findings must be 511 considered. Because of this, it is possible that variants identified in the five patients 512 might genuinely be related to the patients' phenotype and underlie their condition.
513
Secondly, the TruSight One capture kit does not provide a uniform capture across 514 the 18 exons of the FGD1 gene (Figure 1 ). To investigate whether the failure to identify 515 FGD1 mutation in this study is due to sample quality or inherent deficiency of TruSight 516 One kit for capturing FGD1 coding region, normalised read counts across the gene for 517 the eight samples that passed alignment QC compared to 18 controls from the same 518 sequencing batch. Although coverage efficiency significantly differs between exons of the 519 FGD1 (p< 0.001, One-way ANNOVA), capture coverage of the gene for AAS samples is 520 not significantly different between the AAS cases and controls (p= 0.9998, One-tailed 521 t-test) (Figure 2 ). Therefore a possible explanation for the failure to identify FGD1 522 mutations can be the limitations of TruSight One kit for capturing FGD1 exons. In 523 particular exons, 5, 10 and 16 were identified to have low capture coverage in the 524 TruSight One kit.
525
Investigation of mutational spectrum in the coding region of FGD1 revealed that the 526 highest number of novel SNVs map to the exon six but the highest density of 527 mutational events (i.e. number of SNVs per length of the exon) occurs at the exon 13 528 (Figure 3 ). The depth of coverage at both exons was sufficient for variant calling in our 529 study. Only one variant have been identified on each of the exon 5, and exon 10 and no 530 variant have been reported in the exon 16 (Figure 3 ). Total number of SNVs identified 531 in these three exons constitute a mere 5.74% of the total mutational density across the 532 coding length of FGD1 gene, and therefore even with a reduced capture in these exons, 533 we have still been able to robustly screen for pathogenic mutations in the remaining 534 12/36 exons with theoretical 94.25% mutational density. However, given the modest statistical 535 power of targeted exome sequencing for identifying de-novo heterozygous variants [79] , 536 the implication of low capture coverage in these exons for detecting FGD1 variants 537 merits further investigation.
538
Thirdly, the inherent deficiency of targeted exome sequencing in capturing sequences 539 outside the coding region might also explain the lack of FGD1 positive cases in our 540 study. The FGD1 intronic variants (including splicing SNVs) have been reported to 541 underlie AAS [11, 80] . Considering that targeted exome sequencing is ill-suited for 542 identifying variants outside the coding region, we might have missed pathogenic variants 543 in the intronic region.
544
Finally, the mean insert size for the nine samples analysed was ∼143 bp. Low quality 545 DNA or reduced mass input of gDNA changes the distribution of library fragments and 546 result in smaller insert sizes than expected [81] . These smaller fragments are prone to 547 exclusion during the subsequent clean-up step and result in a skewed fragment 548 distribution. In view of this, skewed insert length clearly explains the unevenness in 549 coverage distribution in our samples, especially for the FGD1 gene. In addition, larger 550 read lengths (≥ 170) are identified to provide a more uniform coverage distribution 551 across the genes targeted and reduce the false negative rate in the variant detection by 552 two fold [82] . Although larger read length is achieved at the expense of reduced depth, 553 evenness in the coverage dramatically increases the diagnostic power of exome 554 sequencing [82] . The average size of exons in the human genome is 170 bp, and 80-85% 555 of exons are identified to be <200 bp in size [83, 84] . Consequently, read lengths above 556 170bp provide an ideal size distribution for capturing not only exonic variants but also 557 intronic variants that have implications in splicing. Because of this, skewed read length 558 size in our study might provide an explanation for the reduced diagnostic power to 559 identify the FGD1 mutations in our samples. Given uneven coverage across the exons of 560 FGD1 in the TruSigth one panel and the reduced insert sizes in this study, screening of 561 the FGD1 gene in higher uniform coverage must be prioritised for unresolved cases.
562
While rare disorders are believed to be primarily caused by a single penetrant protein 563 truncating mutation, there are cases in which patients with the same genetic defect 564 present different phenotypes [85] . This variable expressivity is generally attributed to 565 the role of modifier genes that collectively impact the penetrance, dominance, and 566 expressivity of the mutation [86] . Besides, many rare disorders share extensive 567 phenotypic similarity. The lack of granularity in phenotypic manifestations of rare 568 disorders is particularly problematic when it comes to molecular diagnosis. Also there 569 are occasions in which mutations in different genes can result in similar phenotypes [87] . 570 The issue pertaining to the lack of consistency in phenotypic manifestations is more 571 pronounced in the context of neurodevelopmental disorders [88] , mainly because of a 572 large number of genes identified to implicate in the disease pathogenicity [89] . In the 573 absence of detailed phenotypic information, similarities between patients cannot be 574 statistically tested, and the power of NGS analysis is reduced. Obtaining complete and 575 update phenotypic information from patients residing in remote areas in Colombia 576 presented a significant challenge in this study. Indeed, mixed phenotypic information 577 with a variable degree of details and completeness appeared to be the main limitation 578 for molecular diagnosis in these patients. Despite the provisional diagnosis of AAS, 579 many features of the patients are unspecific to AAS. Clinically, this implicates that 580 patients studied here perhaps present a heterogeneous group of disorders that share 581 some phenotypic similarities including CLP, shawl scrotum and hypertelorism (the three 582 most frequent features in the cohort). Interestingly, identification of plausible mutations 583 in five individuals (out of the eight patients satisfied QC criteria) presents a strong case 584 for alternative diagnosis across these patients.
585
To summarise, we applied targeted exome sequencing to 14 patients with the 586 13/36 provisional diagnosis of Aarskog-Scott syndrome. Six samples were discarded from 587 variant analysis early on as they did not comply with the quality standards required for 588 confident variant analysis. Investigation of novel variants in the remaining eight samples 589 resulted in the identification of putative causal variants for five samples including 590 CL021, CL025, CL033, CL035 and CL036 (Table 4) . 591 An important finding from this analysis is the Kabuki syndrome (KS) diagnosis in 592 the patient CL036. Having reviewed the findings with our local clinical experts, we 593 confirmed the Kabuki diagnosis in this patient. While KS was believed to have a higher 594 incidence in Japanese populations, recent findings in other ethnic groups have extended 595 the phenotypic spectrum of the disease and revealed new pathological mutations [90, 91] . 596 Establishing molecular diagnosis in the remaining patients requires further follow-up 597 including in-depth investigation of phenotypic details that may corroborate the 598 molecular finding from WES analysis. 
